FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
1. FDA approved JNJ's Tremfya for Crohn's disease treatment, boosting treatment options. 2. Tremfya sales reached $3.67 billion, a 17% annual increase. 3. Tremfya's approval is based on significant Phase 3 trial results. 4. This is Tremfya's fourth FDA approval, expanding its market potential. 5. Overall market response is neutral; JNJ stock slightly decreased in premarket trading.